Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kupferminc, M. J.
Right arrow Articles by Peyser, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupferminc, M. J.
Right arrow Articles by Peyser, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 5, No. 3, pp. 271-273, 1990
© 1990 European Society of Human Reproduction and Embryology

research-article

A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer

M. J. Kupferminc, J. B. Lessing, A. Amit, I. Yovel, M. P. David and M. R. Peyser

IVF Unit Serline Maternity Hospital Tel-Aviv Medical Centre Sakler School of Medicine Tel-Aviv University 15 Ein Dor Street Tel-Aviv, Israel

A randomized, prospective blind study was carried out to investigate the need for luteal phase support in patients undergoing in-vitro fertilization (IVF). One-hundred-and-fifty-six patients undergoing IVF in cycles stimulated with human menopausal gonadotrophin (HMG) and human chorionic gonadotrophin (HCG) stimulated FVF, were divided into three different groups for luteal phase treatment. Fifty-four patients received dydrogesterone three times daily (TID) beginning on the day of embryo transfer (ET). Fifty-one patients received HCG on days 3, 6 and 10 following ET. Fifty-one patients received placebo p.o. TID beginning on the day of ET. There was no difference between the groups in pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy. The data indicate that supplementation of the luteal phase may not improve the success rates of IVF-ET cycles.

Key words: dydrogesterone/HCG/IVF/luteal phase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
S. Dias, R. McNamee, and A. Vail
Evidence of improving quality of reporting of randomized controlled trials in subfertility
Hum. Reprod., October 1, 2006; 21(10): 2617 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
G. Ragni, W. Vegetti, E. Baroni, M. Colombo, M. Arnoldi, G. Lombroso, and P. G. Crosignani
Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist
Hum. Reprod., November 1, 2001; 16(11): 2258 - 2262.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.